TY  - JOUR
TI  - ASSESSMENT OF THE EFFICACY OF ADALIMUMAB TREATMENT IN HIDRADENITIS SUPPURATIVA: A SINGLE-CENTER STUDY
AB  - Hidradenitis suppurativa (HS), is a chronic disease characterized by recurrent subcutaneous nodules, abscesses, and draining sinuses. Adalimumab is used for moderate to severe HS cases that do not respond to systemic treatments. The aim of our study was to evaluate the efficacy of adalimumab treatment in patients with HS who received treatment at our clinic. The medical records of patients aged 18 years and older who received adalimumab treatment for HS between 2016 and 2021 were retrospectively reviewed. When patients were evaluated in terms of Hidradenitis Suppurativa Clinical Response (HISCR) at the end of 3 months, 6 (31.6%) patients had achieved HISCR within 3 months. After 6 months of treatment, an additional 9 (47.4%) patients had reached the HISCR endpoint. At the end of 6 months, no response was observed in 4 patients (21.1%). Based on the data obtained from the study, adalimumab is considered to be an effective and safe treatment method for moderate to severe HS patients.
AU  - ÖKSÜM SOLAK, EDA
DO  - 10.34108/eujhs.1306589
PY  - 2023
JO  - Sağlık Bilimleri Dergisi
VL  - 32
IS  - 3
SN  - 1018-3655
SP  - 399
EP  - 402
DB  - TRDizin
UR  - http://search/yayin/detay/1212460
ER  -